Literature DB >> 2847072

Chronic administration of morphine and naltrexone up-regulate[3H][D-Ala2,D-leu5]enkephalin binding sites by different mechanisms.

J A Danks1, F C Tortella, J B Long, V Bykov, A E Jacobson, K C Rice, J W Holaday, R B Rothman.   

Abstract

Previous studies have demonstrated that chronic administration of morphine up-regulated the lower affinity binding site for [3H][D-ala2,D-leu5]enkephalin, without producing a detectable alteration in the higher affinity binding site for [3H][D-ala2,D-leu5]enkephalin (Rothman et al., Eur. J. Pharmac. 124: 113-119, 1986). The experiments reported in this paper tested the hypothesis that chronic administration of morphine and naltrexone up-regulated the binding sites for [3H][D-ala2,D-leu5]enkephalin by different mechanisms. Rats were given either morphine or naltrexone chronically. Chronic administration of morphine up-regulated the lower affinity site, while chronic administration of naltrexone up-regulated both the higher and lower affinity binding sites for [3H][D-ala2,D-leu5]enkephalin. Unlike the lower affinity binding site for [3H][D-ala2,D-leu5]enkephalin present in membranes prepared from rats treated with placebo pellets, the lower affinity binding sites which were up-regulated by naltrexone and morphine were partially (naltrexone) or completely (morphine) labile to preincubation for 60 min at 25 degrees C in 50 mM Tris-HCl, pH 7.4, containing 0.4 M NaCl. These data suggest that chronic administration of morphine and naltrexone up-regulate binding sites for [3H][D-ala2,D-leu5]enkephalin through different mechanisms, and that the lower affinity binding sites for [3H][D-ala2, D-leu5]enkephalin which are up-regulated by chronic administration of morphine and naltrexone might differ biochemically from the lower affinity binding sites present in membranes treated with placebo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2847072     DOI: 10.1016/0028-3908(88)90125-6

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  5 in total

1.  Quantitative autoradiography of adenosine receptors in brains of chronic naltrexone-treated mice.

Authors:  Alexis Bailey; Rachel M Hawkins; Susanna M O Hourani; Ian Kitchen
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

Review 2.  Recent advances on the δ opioid receptor: from trafficking to function.

Authors:  Louis Gendron; Nitish Mittal; Hélène Beaudry; Wendy Walwyn
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

3.  Blockade of tolerance to morphine but not to kappa opioids by a nitric oxide synthase inhibitor.

Authors:  Y A Kolesnikov; C G Pick; G Ciszewska; G W Pasternak
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

4.  The interaction of the mu-opioid receptor and G protein is altered after chronic morphine treatment in rats.

Authors:  P L Tao; C R Lee; P Y Law; H H Loh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-11       Impact factor: 3.000

5.  Dopamine D₄ receptor counteracts morphine-induced changes in µ opioid receptor signaling in the striosomes of the rat caudate putamen.

Authors:  Diana Suárez-Boomgaard; Belén Gago; Alejandra Valderrama-Carvajal; Ruth Roales-Buján; Kathleen Van Craenenbroeck; Jolien Duchou; Dasiel O Borroto-Escuela; José Medina-Luque; Adelaida de la Calle; Kjell Fuxe; Alicia Rivera
Journal:  Int J Mol Sci       Date:  2014-01-21       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.